The frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease in healthcare institutions
DOI:
https://doi.org/10.24959/sphhcj.24.335Keywords:
duodenal ulcer; clinical treatment protocol; drugs; frequency analysis, VEN analysis; pharmaceutical provisionAbstract
Aim. To perform the frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease (DUD) in a healthcare institution.
Materials and methods. Depersonalized information base containing data from 112 histories of patients with DUD who were treated in one of the healthcare institutions in Vinnytsia, prescription sheets, the National List of Essential Medicines, the Unified Clinical Protocol of Primary and Specialized Medical Care “Peptic ulcer of the stomach and duodenal ulcer in adults and children” (2023), the State Formulary of Medicines (2023) were used. Research methods such as retrospective, system-analytical, frequency and VEN analysis were applied.
Results. As a result of the frequency and VEN analysis conducted during the study period, doctors prescribed a total of 48 active substances by INN and 109 drugs by trade names (TN). A total of 817 drugs were prescribed by TN. According to the results of this analysis, it was found that the largest number of prescriptions fell on proton pump inhibitors of different generations (21.3 % of all prescriptions) and multienzyme drugs (15.06 % of all prescriptions). For the eradication of Helicobacter pylori, agents for the treatment of peptic ulcer and gastroesophageal reflux disease, combinations for the eradication of Helicobacter pylori were prescribed (14.89 % of all prescriptions). There were also many prescriptions from groups of drugs affecting the digestive system (13.89 %). For the treatment of concomitant pathologies, drugs used to treat the liver and biliary tract (4.28 %), intestinal anti-inflammatory drugs (2.08 %), anti-anemic drugs (1.46 %), antibacterial drugs, antibiotics, hypolipidemic, hypnotic, sedative drugs, antidepressants, etc., were prescribed. It was proved that the main of pharmacotherapy of DUD was etiological and pathogenetic therapy. According to the VEN analysis, 8 drugs (17 %) were included in category V, 22 drugs (46 %) – in category E, and 18 drugs (37 %) – in category N, out of 48 drugs by INN.
Conclusions. Therefore, the study conducted showed that a significant number of prescriptions and financial resources were directed to the use of secondary drugs that were not included in the regulatory legal acts regulating the pharmaceutical provision of patients with DUD.
References
Kniazkova, I. I. (2020). Vyrazkova khvoroba shlunka ta dvanadtsiatypaloi kyshky: aspekty diahnostyky. https://health-ua.com/gastroenterology/kislotozalezni-xvorobi/62210-virazkova-hvoroba-shlunka--ta-dvanadtcyatipalo-kishki--aspekti-dagnostiki
Tkachenko, O. V., & Demydas, O. V. (2023). Deiaki nevrolohichni ta laboratorni pokaznyky pry vyrazkovii khvorobi dvanadtsiatypaloi kyshky v stadii zahostrennia zalezhno vid naiavnosti v patsiientiv Helicobacter pylori. Mizhnarodnyi nevrolohichnyi zhurnal, 19(6), 167–173. https://inj.zaslavsky.com.ua/index.php/journal/article/download/1017/1024/643
.Sonnenberg, A., Turner, K. O., & Genta, R. M. (2020). Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. Am J Gastroenterol, 115(2), 244-250. doi: 10.14309/ajg.0000000000000517
Zakon Ukrainy “Pro osnovy zakonodavstva Ukrainy pro okhoronu zdorovia” No. 2801- ХІІ (1992). https://zakon.rada.gov.ua/laws/show/2801-12
Postanova KMU Ukrainy “Pro zatverdzhennia Derzhavnoi stratehii realizatsii derzhavnoi polityky zabezpechennia naselennia likarskymy zasobamy na period do 2025 roku” No. 1022. (2018). https://www.kmu.gov.ua/npas/pro-zatverdzhennarskimi-zasobami-na-period-do-2025-roku
Herasymova, O. O., & Kuznietsov, I. E. (2013). ABC/VEN/chastotnyi analiz medykamentoznoi terapii vyrazkovoi khvoroby dvanadtsiatypaloi kyshky. U Suchasna medytsyna: aktualni problemy, shliakhy vyrishennia ta perspektyvy rozvytku (10-13). http://dspace.nuph.edu.ua/handle/123456789/10008
Makarenko, O. V., Karimova, M. M., & Masheiko, A. M. (2018). Kliniko-ekonomichnyi analiz likarskykh pryznachen ditiam ta pidlitkam, khvorym na Helicobacter pylori-asotsiiovanu hastroduodenalnu patolohiiu. Farmatsevtychnyi zhurnal, (5-6), 11-23. https://pharmj.org.ua/
Herasymova, O. O., & Zahrebelna, Yu. M. (2010). Farmakoekonomichnyi analiz riznykh rezhymiv antykhelikobakternoi terapii vyrazkovoi khvoroby shlunka ta dvanadtsiatypaloi kyshky. Ratsionalna farmakoterapiia, 4(17), 32-36. http://surl.li/mbrfjh
Herasymova, O. O., & Krasiuk, A. A. (2017). Analiz asortymentu ta dostupnosti likarskykh zasobiv, shcho vykorystovuiutsia v skhemakh antykhelikobakternoi terapii, na farmatsevtychnomu rynku Ukrainy. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, (2), 54-62. http://nbuv.gov.ua/UJRN/Uezyaf_2017_2_9
Yakovleva, O. S. (2016). Kliniko-ekonomichnyi analiz khvorykh na peptychnu vyrazku shlunku dvanadtsiatypaloi kyshky v umovakh statsionaru provela. Sotsialna farmatsiia v okhoroni zdorovia, 2(1), 64-69.http://dspace.zsmu.edu.ua/bitstream/123456789/7627/1/20-32-PB_64-69.pdf
Yakovlieva, L. V., Herasymova, O. O., & Yakymenko, A. I. (2020). Rezultaty ABC/chastotnoho analizu farmakoterapii patsiientiv z peptychnoiu vyrazkoiu shlunku v statsionari. U Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku (s.79-84).
Nakaz “Pro zatverdzhennia Unifikovanoho klinichnoho protokolu pervynnoi ta spetsializovanoi medychnoi dopomohy “Peptychna vyrazka shlunka ta dvanadtsiatypaloi kyshky u doroslykh i ditei”. No. 1514 (2023). https://zakon.rada.gov.ua/go/v1514282-23
Postanova Kabinetu Ministriv Ukrainy “Deiaki pytannia derzhavnoho rehuliuvannia tsin na likarski zasoby i vyroby medychnoho pryznachennia” No. 333 (2009). https://zakon.rada.gov.ua/laws/show/333-2009-%D0%BF#Text
Derzhavnyi formuliar likarskykh zasobiv Ukrainy. (2023). https://moz.gov.ua/uploads/9/47271-dn_1102_16062023_dod.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
